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Background. Mycograb (NeuTec Pharma) is a human recombinant monoclonal antibody against heat shock
protein 90 that, in laboratory studies, was revealed to have synergy with amphotericin B against a broad spectrum
of Candida species.
Methods. A double-blind, randomized study was conducted to determine whether lipid-associated ampho-
tericin B plus Mycograb was superior to amphotericin B plus placebo in patients with culture-confirmed invasive
candidiasis. Patients received a lipid-associated formulation of amphotericin B plus a 5-day course of Mycograb
or placebo, having been stratified on the basis of Candida species (Candida albicans vs. non-albicans species of
Candida). Inclusion criteria included clinical evidence of active infection at trial entry plus growth of Candida
species on culture of a specimen from a clinically significant site within 3 days after initiation of study treatment.
The primary efficacy variable was overall response to treatment (clinical and mycological resolution) by day 10.
Results. Of the 139 patients enrolled from Europe and the United States, 117 were included in the modified
intention-to-treat population. A complete overall response by day 10 was obtained for 29 (48%) of 61 patients
in the amphotericin B group, compared with 47 (84%) of 56 patients in the Mycograb combination therapy group
(odds ratio [OR], 5.8; 95% confidence interval [CI], 2.41–13.79; ). The following efficacy criteria wereP ! .001
also met: clinical response (52% vs. 86%; OR, 5.4; 95% CI, 2.21–13.39; ), mycological response (54% vs.P ! .001
89%; OR, 7.1; 95% CI, 2.64–18.94; ), Candida-attributable mortality (18% vs. 4%; OR, 0.2; 95% CI, 0.04–P ! .001
0.80; ), and rate of culture-confirmed clearance of the infection (hazard ratio, 2.3; 95% CI, 1.4–3.8;Pp .025
). Mycograb was well tolerated.Pp .001
Conclusions. Mycograb plus lipid-associated amphotericin B produced significant clinical and culture-con-
firmed improvement in outcome for patients with invasive candidiasis.
Candidemia remains a costly burden to health care [1].
Candida-attributable mortality rates range from 4.4%–
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8.7% in noninferiority trials of conventional ampho-
tericin B [2, 3] to 10% in observational studies [4] and
15%–49% in case-matched studies [5–7]. Lipid-asso-
ciated formulations of amphotericin B (L-ampho-
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Annual Meeting of the European Congress of Clinical Microbiology and Infectious
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tericin), such as Abelcet (Zeneus) or Ambisome (Gilead), are
preferable to conventional amphotericin B, because the lipid-
associated formulations have a superior safety profile, such that
the efficacy of amphotericin B is not distorted by treatment
withdrawals resulting from its toxicity [8].
The poor outcome for monotherapy and the availability of
new antifungals [8, 9] have kindled interest in combination
therapy [10, 11]. Fluconazole plus 5–6 days of conventional
amphotericin B treatment, compared with fluconazole alone,
has been associated with a trend toward greater success [12].
In the present study of adults with culture-confirmed in-
vasive candidiasis, the objective was to compare L-amphotericin
alone and in combination with Mycograb (NeuTec Pharma), a
human recombinant monoclonal antibody targeting heat shock
protein 90 (hsp90). Hsp90 is a molecular chaperone present in
the fungal cell wall and extracellular material [13] and has been
described as the “Achilles’ heel” of fungi [14]. An hsp90 in-
hibitor (geldanamycin) was found to increase the susceptibility
of Candida and Aspergillus species to fluconazole and caspo-
fungin, respectively, in vitro [15]. The presence of endogenous
antibody to hsp90 closely correlated with recovery in patients
with invasive candidiasis treated with amphotericin B [16]. My-
cograb mimics this naturally occurring inhibitor of hsp90 and
is thus a logical partner in combination therapy. Mycograb has
demonstrated synergy against a broad range of Candida species
in combination with amphotericin B in vitro and in animal
models of invasive candidiasis [13], and different antibodies
against the same hsp90 epitope were protective in murine can-
didiasis [17, 18].
Researchers in studies with single antifungal products have
not reached a consensus on treatment duration and study end
points [19]. If a combination of drugs is more effective than
the single agent, then there should be an improvement in the
clinical and mycological responses in recipients of combination
therapy at a fixed time representing the minimum duration of
monotherapy. The median duration of therapy for Abelcet and
Ambisome is 10–13 days [20–22]. Therefore, the primary time
selected for this study was day 10. The primary variable was
composite, requiring clinical and culture-confirmed resolution
of candidiasis. The interpretation of clinical response is more
subjective if it includes patients who show improvement, as
well as patients who experience cure; thus, patients who had a
partial response were classified among the nonresponders. Sec-
ondary end points included the rate of mycological clearance
over time (removing the limitations of a fixed time point) and
Candida-attributable mortality 4 weeks after receipt of the last
dose of study drug.
Restriction to patients with candidemia was considered to
be inappropriate, because this restriction misses 50% of nec-
ropsy-proven cases (probably more if receiving fluconazole pro-
phylaxis) and potentially leads to an overrepresentation of less-
virulent yeasts, such as Candida parapsilosis [2, 23]. Severely ill
patients (who are often excluded from investigational studies
because of renal or hepatic dysfunction, an estimated duration
of survival of !5 days, or failure of prior antifungal therapy)
were included in this trial [2, 3, 24].
PATIENTS AND METHODS
Study design. The protocol was reviewed by the relevant
ethics committees or institutional review boards; written in-
formed consent was obtained from each patient or legal rep-
resentative before enrollment, and applicable guidelines for hu-
man studies were followed. The trial was conducted in 10
European countries and in the United States during the period
of December 2002 through April 2004, and patients from 26
institutions were recruited.
Enrollment. To be enrolled, patients had to be 18 years
of age and to have had 1 positive Candida culture of a spec-
imen from a clinically significant site within the previous 3
days, as well as at least 1 of the following signs at study entry:
hyperthermia (temperature, 138C), hypothermia (tempera-
ture, !36C), tachycardia (heart rate, 1110 beats/min), hypo-
tension (mean blood pressure, !70 mm Hg), high WBC count
(i.e., 111,000 cells/mm3), left shift, need for vasopressor sup-
port, or other abnormalities consistent with an ongoing infec-
tious disease process. Cultures of samples from significant sites
or specimens included blood cultures and/or cultures of sam-
ples from a deep, normally sterile site. Respiratory secretions,
oropharyngeal specimens, and esophageal specimens were not
considered to be significant, and positive culture results from
these sites were not considered to be indicative of invasive
candidiasis. Patients with endocarditis were excluded.
Study procedures. Patients were stratified into groups on
the basis of Candida species (Candida albicans vs. non-albicans
species of Candida) and were randomly assigned to receive
either intravenous Mycograb (1 mg/kg) or placebo (saline) ev-
ery 12 h for 5 days. In addition, each patient was treated with
the manufacturer’s recommended dose of either Abelcet (5 mg/
kg per day) or Ambisome (3 mg/kg per day) for a minimum
of 10 days. Patients and investigators remained blinded
throughout the study. Apart from systemic antifungal therapy,
no other concomitant medications were censored.
Both mycological and clinical responses were used in the as-
sessment of efficacy. The study drug was given on days 1–5, and
samples were obtained for culture on days 2, 3, 4, 5, 6, 8, and
10 or until the signs and symptoms of infection had resolved
and culture results were repeatedly negative. Clinical response to
treatment was assessed on days 4, 5, 6, 8, 10, and 33, and the
course of the disease over the previous 24 h was assessed on a
daily basis up until day 10. The assessment of clinical response
was made by the local investigator, and the response was con-
sidered to be complete if all signs and symptoms thought to be
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Table 1. Characteristics of patients enrolled and included in the analysis of efficacy
(i.e., the modified intention-to-treat [ITT] population) and analysis of safety (i.e., the
safety population).
Group or finding
No. of patients who
received lipid-associated
amphotericin B
Plus placebo
(n p 71)
Plus Mycograb
(n p 68)
No study drug given 2 0
Safety population
No. of patients 69 68
No positive Candida culture resulta 6 8
No evidence of sepsisb 2 0
Indeterminate evaluation findingsc 0 3
Candida endocarditis 0 1
Modified ITT population
No. of patients 61 56
Symptomatic candiduria 6 7
Deep abdominal drain 1 2
Infected necrotomy site 1 3
Subgroup analyses
Candidemia and/or positive sterile site culture resultsd 53 44
Candidemia 35 33
Positive sterile site culture resultse 32 23
NOTE. Mycograb (NeuTec Pharma) is an antibody-based inhibitor of heat shock protein 90.
a No positive result of Candida culture of a sample from any site within 14 days of study entry (3
patients), or the only positive culture result was from a respiratory secretion (10 patients) or sample from
an insignificant site (1 patient).
b No clinical or laboratory evidence of sepsis at the time of study entry for patients who were not
immunosuppressed.
c Patients died (2 patients) or were withdrawn from the study (1 patient) on the first day of study
treatment, before posttreatment assessments were available.
d Positive results of cultures of samples from a deep, normally sterile site and/or positive blood culture
results.
e Positive results of cultures of samples from a deep, normally sterile site.
due to Candida infection had resolved. An independent expert
and a safety monitoring committee monitored the trial’s safety
during the study. Investigators assessed the relationship of adverse
events to Mycograb and L-amphotericin.
Evaluation of efficacy. The primary efficacy end point was
overall response to treatment on day 10, which was 5 days after
receipt of the last dose of study drug and was the minimum
duration of therapy with L-amphotericin. A favorable overall
response was defined as a complete clinical and mycological
response, with resolution of all signs and symptoms of can-
didiasis and culture-confirmed eradication of the pathogen.
Partial improvement, lack of progress, or worsening of the
candidiasis were classified as unfavorable.
Secondary efficacy end points included clinical response at
day 10, mycological response at day 10, rate of mycological
clearance of the infection, and Candida-attributable mortality
4 weeks after receipt of the last dose of study drug (i.e., day
33). Candida-attributable mortality was defined as a fatality in
which the investigator stated that candidiasis significantly con-
tributed to death and for which there was clinical evidence of
persistent candidiasis, autopsy evidence, and/or death within
48 h after a positive blood culture result [4].
Statistical analysis. Sample size was determined after a pi-
lot study using nQuery 6 (Statistical Solutions). There was one
comparison of interest; therefore, the 5% significance level was
not adjusted. A hierarchical test procedure was applied to sec-
ondary efficacy variables. The rate of mycological clearance used
the time from the baseline positive culture result to the last
positive culture result, and the analysis was censored if the last
positive culture was not observed because the patient was with-
drawn from the study or died.
The prespecified study populations for analysis were the
safety population (i.e., all patients who received 1 dose of
study drug) and the modified intention-to-treat (ITT) popu-
lation (for analysis of efficacy). The modified ITT population
included all patients who had culture-confirmed invasive can-
didiasis and who received at least 1 dose of the study drug and
had at least 1 poststudy treatment assessment.
Table 2. Baseline characteristics of patients in the modified intention-to-treat
population.
Characteristic
Lipid-associated
amphotericin B
Plus placebo
(n p 61)
Plus Mycograb
(n p 56)
Sex
Male 35 (57) 42 (75)
Female 26 (43) 14 (25)
Age, median years (range) 64 (19–88) 58 (21–76)
Underlying condition or risk factor
APACHE II score 118 26 (43) 27 (48)
Stay in an intensive care unit 51 (84) 51 (91)
Charlson weighted index of comorbidity 2.92  1.96 3.42  1.88
Smokinga 10 (16) 23 (41)
Alcoholism 1 (2) 4 (7)
Chronic obstructive pulmonary disease 7 (11) 10 (18)
Intubation 31 (51) 34 (61)
Liver failure 15 (25) 14 (25)
Renal failure 24 (39) 23 (41)
Diabetes mellitus 8 (13) 10 (18)
Vasopressor support requirement 30 (49) 33 (59)
Neutropenia or AIDSb 6 (10) 1 (2)
Corticosteroid use 8 (13) 9 (16)
Other immunosuppression or receipt of chemotherapy 3 (5) 1 (2)
Prior antimicrobial use 53 (87) 48 (86)
Cancer 10 (16) 11 (20)
Receipt of total parental nutrition 10 (16) 12 (21)
Urinary catheter in place 51 (83) 50 (89)
Hemodialysis/peritoneal dialysis 9 (15) 9 (16)
Infection with species other than Candida parapsilosis 58 (95) 55 (98)
APACHE II score
Mean  SD 17.5  6.7 18  7.9
Range 4–32 3–39
Prior receipt of antifungal therapy for 4 days
No. (%) of patients 5 (8) 7 (13)
Duration, mean days (range) 9 (4–21) 8 (4–17)
Candida species
Candida albicans 39 (65) 35 (63)
Candida glabrata 4 (7) 6 (11)
Candida tropicalis 3 (5) 2 (4)
Candida parapsilosis 3 (5) 1 (2)
Candida krusei 2 (3) 0
Unidentified non-albicans species 0 2 (4)
Multiple speciesc 9 (15) 10 (18)
NOTE. Data are no. (%) of patients, unless otherwise indicated. Mycograb (NeuTec Pharma) is an
antibody-based inhibitor of heat shock protein 90.
a Statistically significant ( ).P ! .005
b Neutropenia was defined as a neutrophil count ! cells/L. The patient with AIDS had a CD490.510
cell count ! cells/L.90.210
c In each case, this included C. albicans, with the most common combination being C. albicans and C.
glabrata (6 patients in each group).
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Table 3. Assessment of efficacy in the modified intention-to-treat population.
Variable
No. (%) of patients who
received lipid-associated
amphotericin B
OR  SE 95% CI P
Plus placebo
(n p 61)
Plus Mycograb
(n p 56)
Primary efficacy variable
Complete overall response by day 10 29 (48) 47 (84) 5.762  1.561 2.408–13.787 !.001
Supportive analysesa 29 (48) 47 (84) 6.960  1.273 2.698–17.954 !.001
Receipt of Abelcet or Ambisome 29 (48) 47 (84) 5.846  1.251 2.428–14.077 !.001
Secondary efficacy variable
Complete clinical response by day 10 32 (52) 48 (86) 5.437  1.584 2.207–13.393 !.001
Mycological response by day 10 33 (54) 50 (89) 7.071  1.653 2.640–18.938 !.001
Candida-attributable mortality by day 33 11 (18) 2 (4) 0.168  2.211 0.036–0.797 .025
NOTE. Mycograb (NeuTec Pharma) is an antibody-based inhibitor of heat shock protein 90. Abelcet (Zeneus) and Ambisome (Gilead) are both lipid-associated
formulations of amphotericin B.
a Supportive analyses used the following covariates as factors in the analysis: Candida albicans infection, polyfungal infection, and infection with non-albicans
species of Candida.
A statistical analysis plan was created prior to unblinding by
Hartington Statistics and Data Management (London, UK),
who conducted all prespecified statistical analyses. All binary
outcomes are expressed as ORs with 95% CIs and were analyzed
using logistic regression. The speeds of mycological response
were determined by Cox proportional hazards regression and
Kaplan-Meier plot and are expressed as hazard ratios (HRs)
with 95% CIs.
RESULTS
Baseline characteristics. Of 139 patients enrolled, 117 were
included in the modified ITT population (table 1). Comparison
of baseline characteristics (table 2) revealed that there were no
significant differences in APACHE II scores or in the use of
Abelcet and Ambisome (87% of patients in each treatment
group received Abelcet). The management of central venous
catheters did not differ between the 2 groups, and the catheter
was removed if it was the source of infection [25]. Infected
catheter tips were reported in 12 patients in each group (in the
Mycograb group, catheters were infected with C. albicans for
9 patients, Candida glabrata for 2, and Candida tropicalis for
1; in the placebo group, catheters were infected with C. albicans
for 6 patients, C. glabrata for 1, C. tropicalis for 2, Candida
parapsilosis for 2, and Candida krusei for 1).
Prespecified efficacy analyses. The primary efficacy vari-
able showed a highly statistically significant difference in favor
of combination therapy with Mycograb: only 48% of patients
in the placebo group had a complete clinical and mycological
response by day 10, compared with 84% of patients who re-
ceived combination therapy ( ). Two supportive analysesP ! .001
were performed with respect to species and L-amphotericin
(table 3). Efficacy was consistent between sites.
Clinical response was determined to be complete in 86% of
Mycograb recipients by day 10, compared with 52% of patients
who received placebo ( ). Mycological resolution wasP ! .001
achieved in 89% of Mycograb recipients, compared with 54%
of those in the placebo arm ( ). The rate of mycologicalP ! .001
clearance (by Kaplan-Meier plot) (figure 1) was more than
twice as fast for combination therapy than for amphotericin B
alone (HR, 2.3; 95% CI, 1.4–3.8; ). The Candida-Pp .001
attributable mortality rate decreased from 18% to 4% among
patients receiving Mycograb ( ). Most (12 of 13) Can-Pp .025
dida-attributable deaths occurred by day 12. Overall mortality
in the modified ITT population showed a trend in favor of
combination therapy at day 12 (16% vs. 21%). Most of the
deaths in the placebo group involved patients with APACHE
II scores 25 and were due to Candida infection (figure 2). In
contrast, most frequently, deaths in the Mycograb group in-
volved patients with APACHE II scores 25, and the most
common cause of death was bacterial sepsis, followed by cancer.
Patient subgroup analyses. Subgroup analyses of responses
at day 10 for patients with candidemia, a positive culture result
for a normally sterile site, or both revealed statistically signif-
icant differences in primary and secondary efficacy variables
(table 4). The positive culture results for normally sterile sites
included results for 1 of the following cultures: cultures of
specimens of intravenous line tips ( ), ascite specimensnp 24
( ), laparotomy biopsy specimens ( ), abdominalnp 9 np 17
wound specimens (with positive blood or urine culture results;
), and dialysis catheters ( ) and deep cultures ofnp 3 np 1
specimens from a thoracic wound ( ), pleural spacenp 1
( ), and aortic root prosthesis ( ) or from an autopsynp 1 np 1
( ). Many (27.4%) of these patients also had 1 positivenp 1
urine culture result. The rate of mycological cure was again
more than twice as fast for combination therapy for each sub-
group (for patients with candidemia, the HR was 2.4 [95% CI,
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Figure 1. Kaplan-Meier plot of time to last positive culture result for
patients receiving lipid-associated amphotericin B plus placebo (placebo
group) or plus Mycograb (Mycograb group). Mycograb (NeuTec Pharma)
is an antibody-based inhibitor of heat shock protein 90.
Figure 2. Overall distribution of mortality rates (4 weeks after end of
the study drug treatment regimen) and APACHE II score distribution for
patients receiving lipid-associated amphotericin B plus placebo (placebo
group) or plus Mycograb (Mycograb group). Mycograb (NeuTec Pharma)
is an antibody-based inhibitor of heat shock protein 90.
1.2–4.7; ]; for patients with positive sterile site culturePp .011
results, the HR was 2.6 [95% CI, 1.2–5.8; ]; for patientsPp .020
with candidemia and/or positive sterile site culture results, the
HR was 2.6 [95% CI, 1.4–4.6; ]). The overall mortalityPp .002
rate on day 12 for patients with candidemia in the Mycograb
arm (5 [15%] of 33 patients) was approximately one-half that
of the placebo arm (10 [29%] of 35 patients), but this difference
decreased over time (on day 33, it was 13 [39%] of 33 Mycograb
recipients and 15 [43%] of 35 placebo recipients; by 3 months,
it was 48% for both groups [16 of 33 and 17 of 35 patients,
respectively]).
A subanalysis of nonneutropenic, HIV-negative patients who
were receiving high-dose steroid therapy for preexisting auto-
immune disease, colitis, adrenal insufficiency, respiratory in-
sufficiency complicating chronic obstructive pulmonary dis-
ease, or acute respiratory distress syndrome or as part of
immunosuppression after transplantation revealed that 9 of 9
patients in the Mycograb arm and 4 of 8 in the placebo arm
had a complete response on day 10 ( ), and 2 casesPp .0294
of Candida-attributable mortality occurred in the placebo
group. There were 7 patients with baseline neutropenia or
AIDS, and the low number and unequal distribution of these
patients and the improvement in neutropenia that occurred in
3 of them during the initial 5 days of therapy prevented a
meaningful statistical analysis.
For patients who entered the study for whom 4 days of
prior treatment with systemic antifungals had failed (table 2),
those in the placebo group were less likely to recover (1 [20%]
of 5 patients) than were those in the Mycograb group (4 [57%]
of 7 patients). There were 2 Candida-attributable deaths in the
placebo group.
To identify differences in both the number and the severity
of underlying pathologies (table 2), the Charlson weighted in-
dex of comorbidity was calculated for each patient [26]. The
higher the assigned weight for the disorder, the greater the risk
of death. In both groups, patients who died had a higher Charl-
son weighted index than did survivors (for the placebo group,
vs. [ ]; for the Mycograb3.66 1.88 2.43 1.89 Pp .0166
group, vs. [ ]). In contrast,4.92 3.46 2.41 1.84 Pp .0023
in the placebo group, the mean Charlson weighted index for
patients who had Candida-attributable mortalities (3.092.2)
was similar to that for survivors, which is consistent with can-
didiasis—rather than underlying pathologies—being respon-
sible for death ( ).Pp .38
Recurrences, relapses, and additional antifungal therapy.
Persistent isolations (i.e., isolations of the same species in as-
sociation with the same infection) after day 10 were more com-
mon in the placebo group (13 [21%] of 61 patients) than in the
combination therapy group (4 [7%] of 56 patients). The inci-
dence of new infection (i.e., infection with a different species or,
if the same species, after 2 negative culture results and a re-
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Table 4. Subgroup analyses of candidemia and other forms of invasive candidiasis.
End point, groupa
Proportion of patients (%)
who received lipid-associated
amphotericin B
OR  SE 95% CI P
Plus placebo
(n p 61)
Plus Mycograb
(n p 56)
Overall response by day 10
Candidemia 15/35 (43) 27/33 (82) 6.000  1.761 1.979–18.194 .002
Positive sterile site culture 12/32 (38) 18/23 (78) 6.000  1.866 1.767–20.369 .004
Candidemia and/or positive sterile site culture 21/53 (40) 35/44 (80) 5.926  1.596 2.370–14.814 !.001
Clinical response by day 10
Candidemia 18/35 (51) 27/33 (82) 4.250  1.758 1.407–12.837 .010
Positive sterile site culture 13/32 (41) 19/23 (83) 6.942  1.930 1.914–25.180 .003
Candidemia and/or positive sterile site culture 24/53 (45) 36/44 (82) 5.437  1.614 2.129–13.888 !.001
Mycological response by day 10
Candidemia 18/35 (51) 29/33 (88) 6.845  1.880 1.985–23.600 .002
Positive sterile site culture 13/32 (41) 20/23 (87) 9.744  2.047 2.394–39.657 !.001
Candidemia and/or positive sterile site culture 25/53 (47) 38/44 (86) 7.092  1.679 2.568–19.586 !.001
Candida-attributable mortality
Candidemia 9/35 (26) 2/33 (6) 0.186  2.284 0.037–0.940 .042
Positive sterile site culture 6/32 (19) 0/23 (0) 32 to 5 .035b
Candidemia and/or positive sterile site culture 11/53 (21) 2/44 (5) 0.182  2.223 0.038–0.871 .033
Overall mortality by day 12
Candidemia 10/35 (29) 5/33 (15) 0.446  1.846 0.134–1.484 .188
Positive sterile site culture 6/32 (19) 4/23 (17) 0.912  2.039 0.226–3.687 .897
Candidemia and/or positive sterile site culture 12/53 (23) 8/44 (18) 0.759  1.666 0.279–2.065 .589
NOTE. Mycograb (NeuTec Pharma) is an antibody-based inhibitor of heat shock protein 90.
a These 2 groups overlapped; patients with candidemia may also have had a positive culture result for a sample from a normally sterile site, and vice versa.
b Determined by Fisher’s exact test for Mycograb versus placebo.
corded complete clinical response for the original, treated infec-
tion) was comparable in both groups (7 patients each).
The median (10 days) and mean ( and10.5 5.6 10.0
days for placebo and Mycograb groups, respectively) du-4.4
ration of L-amphotericin treatment were similar in both groups;
however, when premature deaths attributable to Candida in-
fection were excluded, the mean values were and11.48 5.6
days, respectively. Continuation of systemic therapy10.05 4.4
with another antifungal (usually fluconazole) was more com-
mon in the placebo group, increasing the median duration of
treatment to 15.0 days, whereas the duration remained 10 days
in the Mycograb group. The mean duration of treatment for
the placebo group was days, compared with 12.817.8 11.3
7.6 days for the Mycograb group ( ).Pp .0061
This is consistent with a sensitivity analysis performed on
the primary efficacy variable, in which, to be classed as having
experienced a favorable response, patients also had to discon-
tinue all use of systemic antifungals on day 10. This analysis
revealed a highly statistically significant difference between the
2 groups: 52% of patients in the Mycograb group had a com-
plete clinical and mycological response and discontinued sys-
temic antifungal treatment at day 10, compared with 26% of
patients in the placebo group ( ).Pp .005
Safety profile. Adverse events that investigators thought
may have been causally related to receipt of the study drug
occurred in 7 (10%) of Mycograb-treated patients and 5 (7%)
of the placebo-treated patients. In the Mycograb-treated group,
these events included back pain and vomiting ( ); gen-np 1
eralized rash ( ); hypotension and skin blister ( );np 1 np 1
hypertension ( ); septic shock ( ); chills, tachycardia,np 1 np 1
and worsening pyrexia ( ); and low monocyte countnp 1
( ). Temporary, infusion-related back pain also occurrednp 1
in 1 patient in the pilot study (data not shown). Adverse events
thought by the investigator to be causally related to L-ampho-
tericin treatment were less common in the Mycograb-treated
group (table 5).
Comparison of the frequency of all adverse events revealed
that episodes of hypertension occurred more frequently in the
Mycograb group than in the placebo group (5 [7.4%] of 68
patients vs. 2 [2.9%] of 69 patients; ) and usually oc-Pp .27
curred within 2 h after receipt of the first dose of Mycograb
(4 [6%] of 68 patients).
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Table 5. Adverse events believed by the investigator to be causally related to
use of Mycograb or lipid-associated amphotericin B.
Adverse event
Related to
Mycograb use
(n p 68)
Related to
lipid-associated
amphotericin B use
Mycograb
group
(n p 68)
Placebo
group
(n p 69)
Clinical event
Back pain 1 (1.5) … …
Vomiting 1 (1.5) 2 (2.9) 1 (1.4)
Rash 1 (1.5) 1 (1.5) 1 (1.4)
Skin blister 1 (1.5) … …
Hypotension 1 (1.5) 1 (1.5) 2 (2.9)
Hypertension 1 (1.5) … 1 (1.4)
Septic shock 1 (1.5) 1 (1.5) …
Chills 1 (1.5) 3 (4.4) 4 (5.8)
Tachycardia 1 (1.5) 3 (4.4) …
Pyrexia 1 (1.5) 3 (4.4) 3 (4.4)
Renal failure/worsening … … 4 (5.8)
Drug reaction … … 3 (4.4)
Nausea … … 3 (4.4)
Abdominal pain … … 1 (1.4)
Diarrhea … 1 (1.5) …
Laboratory event
Low monocyte count 1 (1.5) 1 (1.5) …
Hypernatremia … … 1 (1.4)
Hypokalemia … 4 (4.4) 5 (7.2)a
Hypocalcemia … … 1 (1.4)
Hyperlipidemia … 1 (1.5) …
Increase in urea and/or creatinine level … 2 (2.9) 2 (2.9)
Anemia … 1 (1.5) 2 (2.9)
Thrombocytopenia … 1 (1.5) …
Increase in liver enzyme level … 2 (2.9) 3 (4.4)
Hematuria … … 1 (1.4)
Proteinuria … … 1 (1.4)
Total no. of events 11 27 39
NOTE. Data are no. (%) of patients. Mycograb (NeuTec Pharma) is an antibody-based inhibitor
of heat shock protein 90.
a An additional 4 patients developed hypokalemia, which was not attributed to amphotericin B
use by the investigator.
DISCUSSION
To be of clinical benefit, a combination therapy regimen must
improve efficacy without producing unacceptable toxicity. The
regimen in the present study achieved this. The improved ef-
ficacy was evident from the increased frequency of clinical and
mycological resolution at a fixed point (day 10; from 48% to
84%; ), representing the minimum duration of L-P ! .001
amphotericin therapy, the reduced Candida-attributable mor-
tality rate 4 weeks after completing study treatment (from 18%
to 4%; ), and culture-confirmed clearance of the in-Pp .025
fection occurring more than twice as quickly ( ). Res-Pp .001
olution of infection in the placebo group was consistent with
that obtained in clinical practice (30% of 923 adult patients
and 37% of 174 pediatric patients, with candidiasis being cured
by Abelcet, with an additional 30% of adults and 21% of pe-
diatric patients showing improvement) [22, 27].
Likewise, patients with candidemia who received Mycograb
were more likely to show an overall response (82% vs. 43%;
), a clinical response (82% vs. 51%; ), and aPp .002 Pp .01
mycological response (88% vs. 51%; ) at day 10. TheyPp .002
also cleared their infections twice as quickly (HR, 2.4; Pp
) and had a reduced rate of Candida-attributable mortality.011
(6% vs. 26%; ).Pp .04
Both mean APACHE II scores (17.5–18.0) and Candida-
attributable mortality rates in the placebo arm were higher than
in recent investigational studies, which have reported lower
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APACHE II scores (mean scores, 13.8–15.4) and Candida-
attributable mortality rates (4.4%–8.7%), probably reflecting
more-exacting exclusion criteria and a higher proportion of C.
parapsilosis infections (16%–20%) [2, 3]. In a large observa-
tional study ( ) in which the mean APACHE II scorenp 1447
(18.6) was higher than in these recent investigational studies,
a higher rate of Candida-attributable mortality (14%) occurred
among C. albicans–infected patients [4]. For C. parapsilosis, this
rate was 2%. In studies that correlated early deaths (within 7
days of candidemia) with candidiasis, the mortality rates were
21% [28] and 22% [29].
Candidiasis was the most common cause of death in the pla-
cebo group, whereas the most common cause in the Mycograb
group was multiple-organ failure secondary to bacterial sepsis.
This was usually due to gram-negative bacterial infection and
was often associated with complications of abdominal surgery.
Recent or concomitant bacteremia, abdominal surgery, deep or-
gan involvement, and multiple-organ failure all correlate with a
poor prognosis in patients with candidiasis [22, 28–30].
Mycograb was well tolerated. Occasionally, patients expe-
rienced back pain, but the pain was transient, and neither the
investigator nor the patient wished to discontinue therapy.
Hypertension developed in 6% of patients within 2 h after
receipt of the first dose of Mycograb; these patients had been
receiving vasopressor support for sepsis-related hypotension
at the time of study entry. Such patients should have their
blood pressure monitored, particularly after receiving their
first dose of Mycograb.
Hsp90 in normal cells is intracellular and released only on
necrosis [31]. In certain cancers and yeasts, it is expressed on
the cell surface, becoming a target for combination therapy,
with hsp90 inhibition making the cell more susceptible to the
second agent [14, 15, 32–34]. In cancer cells, antibody against
hsp90 causes loss of invasiveness [35]. The liberation of hsp90
from yeast or necrotic human cells will activate endothelial
nitric oxide synthase, leading to the release of nitric oxide—a
vasodilator and a potent inhibitor of platelet aggregation [36,
37]. Heat-induced, hsp90-mediated peripheral vasodilatation
in a human volunteer was reversed by hsp90 inhibition with
geldanamycin [38]. Hsp90 activated the prekallikrein–high mo-
lecular weight kininogen complex on endothelial cells, resulting
in bradykinin release [39]. This activity was reversed by an
antibody against hsp90, and this system has been suggested as
a counter-balance to the plasma rennin-angiotensin system
[40]. Therefore, the cases of rebounded hypertension seen after
receipt of the first dose of Mycograb could have been due to
the rapid neutralization of high levels of circulating, vasodila-
tation-inducing hsp90.
Mycograb provides a new approach to the treatment of fun-
gal infections, mimicking the host’s natural protective antibody.
Hsp90 inhibitors not only have direct antifungal activity, but
they may also prevent fungi from developing resistance to flu-
conazole or caspofungin [14, 15]. Furthermore, the binding of
Mycograb to circulating hsp90 may have additional clinical
benefit in reversing hsp90-induced hypotension. These features
make Mycograb a novel and unique antifungal.
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